Oncology vs Cardiology Market Comparison
Two giant TAs. Very different economics.
A decision-grade comparison of oncology and cardiology — market size, growth dynamics, modality mix, deal flow and pipeline density — for portfolio teams choosing where to lean in.
"Should our next bet sit in oncology or cardiology — and why?"
Oncology is the larger and faster-growing TA with rich modality innovation and aggressive deal pricing; cardiology is more volume-driven with rebuilding interest in obesity-adjacent metabolic-cardio assets and gene therapy.
Oncology and cardiology are two of the largest therapy areas in pharma — and yet the strategic decisions inside each are nothing alike. A team picking between them needs more than headline TAMs.
The economics tell two different stories
Oncology premium pricing, biomarker-driven segmentation and high deal multiples make it the playground of choice for innovation-led players. Cardiology is more about volume, adherence and outcome-trial economics — but recent metabolic-cardio convergence (GLP-1, RNAi, gene therapy) has changed that calculus.
Modality compatibility wins the call
The right TA for any pharma is the one where its modality and manufacturing capability meets the lowest competitive density. ADC and bispecific platforms favor oncology; lipid nanoparticle, RNAi and gene-editing platforms increasingly favor cardio-metabolic.
Run both as live models
Decision teams should model both TAs as live opportunity boards — pipeline, deal and pricing data updating monthly — instead of one-time slide-deck comparisons.
What we’re seeing in the data.
Oncology dominates value, cardiology dominates volume
Oncology drives ~35% of pharma growth on premium pricing; cardiology serves >500M patients globally but at much lower per-patient revenue.
Modality density is reshaping cardiology
GLP-1 spillover, RNAi (Inclisiran), gene editing for rare lipid disorders, and AI-driven imaging are reviving the TA.
Deal premiums diverge sharply
Oncology deals routinely clear at 8–15× peak sales; cardiology deals price closer to 4–7× outside breakthrough modalities.
Trial economics are improving for cardio
Outcome-trial costs remain high but adaptive design and digital endpoints are starting to bring trial cost-per-asset down.
How to think about it.
-
01
Compare on net opportunity, not headline TAM
Strip out generic-eroded segments to see addressable whitespace.
-
02
Map modality fit to your capabilities
Cell & gene, ADC and bispecific innovation favors specific manufacturing and platform capabilities.
-
03
Score competitive density
Count credible Phase 2/3 assets per indication — cardiology has fewer credible competitors per segment.
-
04
Run BD price-realism check
Apply current deal multiples to forecast peak sales — discrepancies expose mispriced opportunities.
-
05
Decide the entry gate (in-house vs licensing)
Oncology often demands deal-led entry; cardio rewards in-house platform plays in metabolic-cardio.
What separates a good answer from a defensible one.
Oncology premium pricing faces growing HTA pressure outside the US.
Cardio outcome trials remain expensive — model trial cost as part of asset NPV.
Oncology combinations split economics; cardio combinations rare but adherence-sensitive.
Cardio benefits more from RWE in payer negotiations than oncology does.
Where the signal comes from.
Common questions.
Which TA is more crowded today?
Oncology — significantly. Especially solid-tumor IO and ADC-driven indications.
Where is cardio interest reviving?
Metabolic-cardio (GLP-1 spillover), RNAi for hypercholesterolemia, gene therapy for rare lipid disorders.
How should small biotechs choose between TAs?
Match modality strength and capital runway to TA-specific deal economics; don’t chase the larger TAM blindly.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist